RxSight, Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 62/100
What the filing says
RxSight reported Q2 2026 total revenue of $33.7M (flat vs. $33.6M prior year), including $6.5M from new Alcon strategic collaboration; product sales declined 19% to $27.2M on competitive pressure. Company appointed Aziz Mottiwala as new CEO and withdrew 2026 guidance pending business review. Cash position strong at $208.8M; net loss $12.1M ($0.29/share) vs. $11.8M prior year.
Why this rating
Leadership change + major $200M collaboration deal meaningful for $504M company; but product sales decline and guidance withdrawal temper near-term outlook. Strong cash cushion mitigates concern.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.